June 05, 2024
2 min watch
Save
VIDEO: Phase 2 data focus on pan-VEGF blockers, tyrosine kinase inhibitors in AMD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SEATTLE — In this video from the ARVO meeting, Jay Chhablani, MD, discusses data on pan-VEGF blockers and tyrosine kinase inhibitors for age-related macular degeneration.
In poster presentations, EyePoint Pharmaceuticals discussed its extended delivery systems, while Ocular Therapeutix presented data on tyrosine kinase inhibitors.
“Some of the phase 2 trial data on pan-VEGF blockers, as well as tyrosine kinase inhibitors, were presented [at the ARVO meeting],” Chhablani, professor of ophthalmology at University of Pittsburgh School of Medicine, said. “We are really excited to see how these phase 2 data show up in phase 3.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Chhablani reports consulting for EyePoint Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.